Akebia Therapeutics Stock Forecast, Price & News (NASDAQ:AKBA) Downgraded by BidaskClub to Strong Sell

Akebia Therapeutics Stock Forecast, Price & News stock has undergone multiple analysts rating changes in the recent past.  Akebia Therapeutics Stock Forecast, Price & News Downgraded by BidaskClub on 9/28/2020. In a note to investors, the firm issued a new rating of Strong Sell. The analysts previously had rating of Sell.

Shares of Akebia Therapeutics Stock Forecast, Price & News traded up $0.02 on Monday, reaching $2.48. 4766 shares of the stock traded hands, compared to its average volume of 8684393. Shares of Akebia Therapeutics Stock Forecast, Price & News were trading at $2.48 on Monday. The firm’s 50 day moving average is $8.33 and its 200 day moving average is $8.89.Akebia Therapeutics Stock Forecast, Price & News  has a 12 month low of $2.46 and a 12 month high of $13.71. While on yearly highs and lows, Akebia Therapeutics Stock Forecast, Price & News’s today has traded high as $2.64 and has touched $2.46 on the downward trend. See More Analyst Rating at: RATING

Akebia Therapeutics Stock Forecast, Price & News Earnings and What to expect: 

Akebia Therapeutics last released its earnings data on August 10th, 2020. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. The company had revenue of $90.14 million for the quarter, compared to the consensus estimate of $76.24 million. Akebia Therapeutics has generated ($1.63) earnings per share over the last year. Akebia Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 10th, 2020 based off prior year’s report dates.

Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.50) to ($0.62) per share. The P/E ratio of Akebia Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Akebia Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Akebia Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • 2.55%
  • On 6/8/2020 Director Maxine Gowen Sell 4,567 at average share price of $11.84 which equates to $54,073.28 in money value.
  • On 6/1/2020 Insider Dell Faulkingham Sell 6,426 at average price of  $11.58 with total value of : $74,413.08
  • On 2/28/2020 CFO Jason Amello Sell 6,976 at average price of  $8.70 with total value of : $60,691.20

Other owners latest trading in Akebia Therapeutics Stock Forecast, Price & News :

  • On 9/15/2020 shares held by Two Sigma Advisers LP were 192,601 which equates to market value of $2.62M and appx 0.00% owners of Akebia Therapeutics Stock Forecast, Price & News
  • On 9/4/2020 shares held by Principal Financial Group Inc. were 93,534 which equates to market value of $1.27M and appx 0.00% owners of Akebia Therapeutics Stock Forecast, Price & News
  • On 9/4/2020 shares held by Teachers Retirement System of The State of Kentucky were 39,605 which equates to market value of $0.54M and appx 0.00% owners of Akebia Therapeutics Stock Forecast, Price & News
  • In total Institutional ownership equates to Institutional Ownership Percentage: 76.75% for Akebia Therapeutics Stock Forecast, Price & News

Analyst at BidaskClub are also talking about :

  • 9/28/2020 – ZoomInfo Technologies was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. (View)
  • 9/28/2020 – ChipMOS Technologies was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. (View)
  • 9/28/2020 – FirstService was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating. (View)
  • 9/28/2020 – Blue Bird was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating. (View)

Akebia Therapeutics Stock Forecast, Price & News (NASDAQ:AKBA) Moving Average Technical Analysis

5 day Moving Average is $2.62 And 5 day price change is -$0.32 (-11.43%)  with average volume for 5 day average is 8,149,480. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.16 and 20 day price change is -$7.70 (-75.64%) and average 20 day moving volume is 12,492,325. 50 day moving average is $8.33  and 50 day price change is -$9.80 ( -79.80%)  and with average volume for 50 days is : 5,585,902. 200 day moving average is $8.89  and 200 day price change is -$3.93 (-61.31%)  and with average volume for 200 days is : 2,574,649.

See More Analyst Rating at: RATING